Log In
BCIQ
Print this Print this
 

HTI-1316

  Manage Alerts
Collapse Summary General Information
Company Jiangsu Hengrui Medicine Co. Ltd.
DescriptionHumanized mAb against programmed cell death 1 ligand 1 (PD-L1; B7-H1; CD274)
Molecular Target Programmed cell death 1 ligand 1 (PD-L1) (B7-H1) (CD274)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard IndicationSolid tumors
Indication DetailsTreat PD-L1-positive advanced tumors
Regulatory Designation
PartnerHengrui Therapeutics Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today